» Articles » PMID: 34691009

So Many Diagnostic Tests, So Little Time: Review and Preview of Testing in Clinical and Public Health Laboratories

Overview
Journal Front Microbiol
Specialty Microbiology
Date 2021 Oct 25
PMID 34691009
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

The recognition of a new yeast, , in 2009 in East Asia, and its rapid global spread, was a reminder of the threats posed by multidrug-resistant fungal pathogens. had likely remained unrecognized for a long time as accurate tests were not available. The laboratory community responded to the challenge by publishing 35 new or revised diagnostic methods between 2014 and early 2021. The commercial sector also modified existing diagnostic devices. These diagnostic tests run the gamut from traditional culture-based differential and selective media, biochemical assimilations, and rapid protein profiles, as well as culture-independent DNA-based diagnostics. We provide an overview of these developments, especially the tests with validation data that were subsequently adopted for common use. We share a workflow developed in our laboratory to process over 37,000 surveillance samples and 5,000 isolates from the outbreak in the New York metropolitan area. Our preview covers new devices and diagnostic approaches on the horizon based on microfluidics, optics, and nanotechnology. Frontline laboratories need rapid, cheap, stable, and easy-to-implement tests to improve diagnosis, surveillance, patient isolation, admission screening, and environmental control. Among the urgent needs is a lateral flow assay or similar device for presumptive identification. All laboratories will benefit from devices that allow rapid antifungal susceptibility testing, including detection of mutations conferring drug resistance. Hopefully, multiplex test panels are on the horizon for synergy of testing with ongoing surveillance of other healthcare-associated infections. genome analysis has a proven role for outbreak investigations, and diagnostic laboratories need quick access to regional and national genome analysis networks.

Citing Articles

Simulating a travel-related origin of in New York-New Jersey.

Verma R, Kiegle E, Keyel A, Chaturvedi S, Chaturvedi V Microbiol Spectr. 2024; 13(2):e0206524.

PMID: 39699207 PMC: 11792543. DOI: 10.1128/spectrum.02065-24.


Assessment of LAMPAuris for Rapid Detection of Candida auris in Clinical Specimens.

Yamamoto M, Alshahni M, Komori A, Mimaki M, Makimura K Mycopathologia. 2024; 189(5):87.

PMID: 39312077 DOI: 10.1007/s11046-024-00892-9.


A lateral flow immunoassay for the rapid identification of from isolates or directly from surveillance enrichment broths.

Chalin A, Arvor A, Hervault A, Plaisance M, Niol L, Simon S Front Microbiol. 2024; 15:1439273.

PMID: 39021636 PMC: 11252032. DOI: 10.3389/fmicb.2024.1439273.


A simple and sensitive test for colonization, surveillance, and infection control suitable for near patient use.

Banik S, Ozay B, Trejo M, Zhu Y, Kanna C, Santellan C J Clin Microbiol. 2024; 62(7):e0052524.

PMID: 38888304 PMC: 11250521. DOI: 10.1128/jcm.00525-24.


First imported case of Candida auris infection in Milan, Italy: genomic characterisation.

Rimoldi S, Nodari R, Rizzo A, Tamoni A, Longobardi C, Pagani C Infection. 2024; 52(4):1633-1638.

PMID: 38557967 PMC: 11289026. DOI: 10.1007/s15010-024-02232-x.


References
1.
Mylonakis E, Clancy C, Ostrosky-Zeichner L, Garey K, Alangaden G, Vazquez J . T2 magnetic resonance assay for the rapid diagnosis of candidemia in whole blood: a clinical trial. Clin Infect Dis. 2015; 60(6):892-9. DOI: 10.1093/cid/ciu959. View

2.
Eddouzi J, Hofstetter V, Groenewald M, Manai M, Sanglard D . Characterization of a new clinical yeast species, Candida tunisiensis sp. nov., isolated from a strain collection from Tunisian hospitals. J Clin Microbiol. 2012; 51(1):31-9. PMC: 3536206. DOI: 10.1128/JCM.01627-12. View

3.
Theill L, Dudiuk C, Morales-Lopez S, Berrio I, Rodriguez J, Marin A . Single-tube classical PCR for Candida auris and Candida haemulonii identification. Rev Iberoam Micol. 2018; 35(2):110-112. DOI: 10.1016/j.riam.2018.01.003. View

4.
Sexton D, Bentz M, Welsh R, Litvintseva A . Evaluation of a new T2 Magnetic Resonance assay for rapid detection of emergent fungal pathogen Candida auris on clinical skin swab samples. Mycoses. 2018; 61(10):786-790. DOI: 10.1111/myc.12817. View

5.
Sexton D, Kordalewska M, Bentz M, Welsh R, Perlin D, Litvintseva A . Direct Detection of Emergent Fungal Pathogen Candida auris in Clinical Skin Swabs by SYBR Green-Based Quantitative PCR Assay. J Clin Microbiol. 2018; 56(12). PMC: 6258843. DOI: 10.1128/JCM.01337-18. View